Indivior Pharmaceuticals (NASDAQ: INDV) revenue
Indivior Pharmaceuticals reported revenue of $1,239m for fiscal 2025, 4.3% more than in fiscal 2024 ($1,188m). Since fiscal 2023 its revenue has grown by 13.4%, an average growth of 6.5% a year.
Indivior Pharmaceuticals has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 3 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,239m | +4.3% | $262.0m | 21.1% |
| 2024 | $1,188m | +8.7% | $38.0m | 3.2% |
| 2023 | $1,093m | — | −$152.0m | −13.9% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Indivior Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Indivior Pharmaceuticals ranks 138th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Indivior Pharmaceuticals, 4.3%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 136th | Progyny | $1,289m | 10.4% |
| 137th | Tempus AI | $1,272m | 83.4% |
| 138th | Indivior Pharmaceuticals | $1,239m | 4.3% |
| 139th | Bio-Techne | $1,215m | −0.4% |
| 140th | Omnicell | $1,185m | 6.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Indivior Pharmaceuticals
- How much revenue did Indivior Pharmaceuticals make in fiscal 2025?
- Indivior Pharmaceuticals reported revenue of $1,239m for fiscal 2025, compared with $1,188m in fiscal 2024.
- How much has the revenue of Indivior Pharmaceuticals grown?
- Between fiscal 2023 and fiscal 2025 it went from $1,093m to $1,239m: 13.4% more, an average growth of 6.5% a year.
- What was the best year for revenue at Indivior Pharmaceuticals?
- Of its last 3 fiscal years, fiscal 2025, with $1,239m.
- Where does Indivior Pharmaceuticals rank in its sector by revenue?
- It ranks 138th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Indivior Pharmaceuticals come from?
- From the annual report (Form 10-K) that Indivior Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Indivior Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Indivior Pharmaceuticals: the Indivior Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.